Cargando…
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
BACKGROUND: Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal diseases regardless of the presence of diabetes mellitus. However, studies evalua...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724001/ https://www.ncbi.nlm.nih.gov/pubmed/36483765 http://dx.doi.org/10.4330/wjc.v14.i11.599 |
_version_ | 1784844316054650880 |
---|---|
author | Olagunju, Abdulbaril Yamani, Naser Kenny, Dorothy Mookadam, Martina Mookadam, Farouk Unzek, Samuel |
author_facet | Olagunju, Abdulbaril Yamani, Naser Kenny, Dorothy Mookadam, Martina Mookadam, Farouk Unzek, Samuel |
author_sort | Olagunju, Abdulbaril |
collection | PubMed |
description | BACKGROUND: Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal diseases regardless of the presence of diabetes mellitus. However, studies evaluating the role of SGLT2-Is in metabolic syndrome (MetS) are limited. AIM: This study primarily aimed to evaluate the impact of SGLT2-Is on the components of MetS. METHODS: Two independent reviewers and an experienced librarian searched Medline, Scopus and the Cochrane central from inception to December 9, 2021 to identify placebo controlled randomized controlled trials that evaluated the impact of SGLT2-Is on the components of MetS as an endpoint. Pre- and post-treatment data of each component were obtained. A meta-analysis was performed using the RevMan (version 5.3; Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration). RESULTS: Treatment with SGLT2-Is resulted in a decrease in fasting plasma glucose (–18.07 mg/dL; 95%CI: -25.32 to –10.82), systolic blood pressure (–1.37 mmHg; 95%CI: -2.08 to –0.65), and waist circumference (–1.28 cm; 95%CI: -1.39 to –1.18) compared to placebo. The impact on high-density lipoprotein cholesterol was similar to placebo (0.01 mg/dL; 95%CI: -0.05 to 0.07). CONCLUSION: SGLT2-Is have a promising role in the management of MetS. |
format | Online Article Text |
id | pubmed-9724001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-97240012022-12-07 Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis Olagunju, Abdulbaril Yamani, Naser Kenny, Dorothy Mookadam, Martina Mookadam, Farouk Unzek, Samuel World J Cardiol Meta-Analysis BACKGROUND: Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal diseases regardless of the presence of diabetes mellitus. However, studies evaluating the role of SGLT2-Is in metabolic syndrome (MetS) are limited. AIM: This study primarily aimed to evaluate the impact of SGLT2-Is on the components of MetS. METHODS: Two independent reviewers and an experienced librarian searched Medline, Scopus and the Cochrane central from inception to December 9, 2021 to identify placebo controlled randomized controlled trials that evaluated the impact of SGLT2-Is on the components of MetS as an endpoint. Pre- and post-treatment data of each component were obtained. A meta-analysis was performed using the RevMan (version 5.3; Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration). RESULTS: Treatment with SGLT2-Is resulted in a decrease in fasting plasma glucose (–18.07 mg/dL; 95%CI: -25.32 to –10.82), systolic blood pressure (–1.37 mmHg; 95%CI: -2.08 to –0.65), and waist circumference (–1.28 cm; 95%CI: -1.39 to –1.18) compared to placebo. The impact on high-density lipoprotein cholesterol was similar to placebo (0.01 mg/dL; 95%CI: -0.05 to 0.07). CONCLUSION: SGLT2-Is have a promising role in the management of MetS. Baishideng Publishing Group Inc 2022-11-26 2022-11-26 /pmc/articles/PMC9724001/ /pubmed/36483765 http://dx.doi.org/10.4330/wjc.v14.i11.599 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Meta-Analysis Olagunju, Abdulbaril Yamani, Naser Kenny, Dorothy Mookadam, Martina Mookadam, Farouk Unzek, Samuel Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis |
title | Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis |
title_full | Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis |
title_fullStr | Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis |
title_full_unstemmed | Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis |
title_short | Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis |
title_sort | potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: a systematic review and meta-analysis |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724001/ https://www.ncbi.nlm.nih.gov/pubmed/36483765 http://dx.doi.org/10.4330/wjc.v14.i11.599 |
work_keys_str_mv | AT olagunjuabdulbaril potentialforsodiumglucosecotransporter2inhibitorsinthemanagementofmetabolicsyndromeasystematicreviewandmetaanalysis AT yamaninaser potentialforsodiumglucosecotransporter2inhibitorsinthemanagementofmetabolicsyndromeasystematicreviewandmetaanalysis AT kennydorothy potentialforsodiumglucosecotransporter2inhibitorsinthemanagementofmetabolicsyndromeasystematicreviewandmetaanalysis AT mookadammartina potentialforsodiumglucosecotransporter2inhibitorsinthemanagementofmetabolicsyndromeasystematicreviewandmetaanalysis AT mookadamfarouk potentialforsodiumglucosecotransporter2inhibitorsinthemanagementofmetabolicsyndromeasystematicreviewandmetaanalysis AT unzeksamuel potentialforsodiumglucosecotransporter2inhibitorsinthemanagementofmetabolicsyndromeasystematicreviewandmetaanalysis |